Investment
Features
FeesSafety
Academy
More
Pluang+

Bonterra's Barry gold project PEA shows strong economics with C$665M NPV and 54% IRR at US$3,500/oz gold price

Company Fundamentals
14 Oct 2026
Newsfile Corp
View Source
Bullish
Bonterra's Barry gold project PEA shows strong economics with C$665M NPV and 54% IRR at US$3,500/oz gold price

Bonterra Resources announced a positive preliminary economic assessment (PEA) for its Barry gold project in Quebec, estimating an after-tax NPV of C$665 million and an IRR of 54% based on a gold price of US$3,500 per ounce. The project plans to produce about 87,097 ounces of gold annually over 7.2 years, with initial capital costs of C$119 million and total sustaining costs of C$354 million. The PEA highlights robust economics with a payback period of 2.5 years and significant upside potential as only 40% of the resource is included in the current mine plan. Next steps include further exploration and development under a joint venture with Gold Fields, which can earn a 70% interest by spending C$30 million.

Bonterra Resources' Barry Project preliminary economic assessment is the subject. For readers following US stocks on Pluang, here is the market snapshot as of Oct 14, 2026 15:41 WIB: out of 150 priced US stocks, 103 rose and 41 fell. Notable movers include IQ at USD 1.01 (+1.86%), GME at USD 27.68 (+1.67%), and BLK at USD 1,083.00 (+1.58%).

More News

CodeWall raises $4M to launch AI-driven autonomous attack agents for continuous enterprise security testing.

CodeWall raises $4M to launch AI-driven autonomous attack agents for continuous enterprise security testing.

CodeWall Ltd. has emerged from stealth with $4 million in pre-seed funding to develop AI-powered autonomous attack agents that simulate real-world cyberattacks on enterprises. These agents start from outside the network with no insider access, contin...

Others
Bullish
1 hour ago
Matchpoint Therapeutics names John O’Malley as Chief Medical Officer to advance autoimmune drug pipeline.

Matchpoint Therapeutics names John O’Malley as Chief Medical Officer to advance autoimmune drug pipeline.

Matchpoint Therapeutics has appointed John O’Malley, M.D., Ph.D., as its Chief Medical Officer. Dr. O’Malley brings extensive experience in immunology and clinical development from his previous roles at CRISPR Therapeutics and Sanofi. His leadership ...

Market News
Bullish
2 hours ago
FDA accepts Orvida Pharma's KM-023 into Rare Disease Evidence Principles process for Olmsted syndrome

FDA accepts Orvida Pharma's KM-023 into Rare Disease Evidence Principles process for Olmsted syndrome

Orvida Pharma announced that the FDA has accepted its lead drug candidate KM-023 (ontivatrep) into the Rare Disease Evidence Principles (RDEP) process for treating Olmsted syndrome, a rare genetic skin disorder. This acceptance allows Orvida to engag...

Market News
Bullish
2 hours ago
DMC Global to release Q3 2026 financial results on October 27 after market close

DMC Global to release Q3 2026 financial results on October 27 after market close

DMC Global Inc. will announce its financial results for the third quarter ending September 30, 2026, on October 27 after the stock market closes. The company will hold a conference call and webcast to discuss the results, providing investors with ins...

Company Fundamentals
Neutral
2 hours ago
Radware launches MCP Server Protection to secure AI integration layers from attacks and abuse.

Radware launches MCP Server Protection to secure AI integration layers from attacks and abuse.

Radware introduced its Model Context Protocol (MCP) Server Protection solution to help organizations secure the integration layer where AI agents connect to enterprise applications and workflows. This new security tool provides visibility into MCP in...

Market News
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App